{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:14:11Z","timestamp":1784258051171,"version":"3.55.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>Perihilar cholangiocarcinoma (phCCA) has excellent outcomes following liver transplantation (LT). Neoadjuvant radiation-based locoregional therapy is standard-of-care. Gemcitabine and cisplatin (gem\/cis) combination systemic therapies have improved outcomes in advanced settings, but their efficacy pre-LT has not been studied.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We review our experience following neoadjuvant gem\/cis alone versus radiation-based approaches. Patients with phCCA undergoing LT at a single center between January 2008 and February 2023 were identified retrospectively. Neoadjuvant therapy was categorized as gem\/cis systemic therapy (ST) alone, or any ST and radiotherapy (RT). Outcomes were posttransplant overall survival (OS), recurrence-free survival (RFS), waitlist time, and pathologic tumor response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>During study period, 27 phCCA patients underwent LT. One patient decompensated with neoadjuvant therapy and was excluded. Median age was 61 y (interquartile range, 53\u201368 y) and 14 (54%) were male. Of 26 patients, 12 (46%) received ST and 14 (54%) RT. Six RT patients received gem\/cis ST. Median waitlist time was 199 d (interquartile range, 98\u2013405 d) and did not differ by neoadjuvant regimen. Explanted tumors were predominantly T1 stage, without lymphovascular invasion or nodal involvement. Neither pathologic features nor percent tumor necrosis differed by regimen. OS probabilities at 1 and 3 y were 84% and 55% for the cohort. There was no significant difference in OS and RFS when stratified by regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>Post-LT OS, RFS, waitlist time, and tumor response were similar in the 2 groups. Patients with phCCA who do not undergo RT may still be considered for LT under appropriate institution-based protocols that adhere to other established criteria.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/txd.0000000000001760","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T20:01:01Z","timestamp":1738958461000},"page":"e1760","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Neoadjuvant Multiagent Systemic Therapy Approach to Liver Transplantation for Perihilar Cholangiocarcinoma"],"prefix":"10.1097","volume":"11","author":[{"given":"Nadine","family":"Soliman","sequence":"first","affiliation":[{"name":"Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashton A.","family":"Connor","sequence":"additional","affiliation":[{"name":"Department of Surgery, Houston Methodist Hospital, Houston, TX."},{"name":"Department of Surgery, Weill Cornell Medical College, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Saharia","sequence":"additional","affiliation":[{"name":"Department of Surgery, Houston Methodist Hospital, Houston, TX."},{"name":"Department of Surgery, Weill Cornell Medical College, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudha","family":"Kodali","sequence":"additional","affiliation":[{"name":"Sherrie and Alan Conover Center for Liver Disease and Transplantation, Department of Medicine, Houston Methodist Hospital, Houston, TX."},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elaileh","sequence":"additional","affiliation":[{"name":"Department of Surgery, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khush","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Surgery, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Semaan","sequence":"additional","affiliation":[{"name":"Department of Surgery, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamneet","family":"Basra","sequence":"additional","affiliation":[{"name":"Sherrie and Alan Conover Center for Liver Disease and Transplantation, Department of Medicine, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Victor","sequence":"additional","affiliation":[{"name":"Sherrie and Alan Conover Center for Liver Disease and Transplantation, Department of Medicine, Houston Methodist Hospital, Houston, TX."},{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J.","family":"Simon","sequence":"additional","affiliation":[{"name":"Department of Surgery, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Lee","family":"Cheah","sequence":"additional","affiliation":[{"name":"Department of Surgery, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Hobeika","sequence":"additional","affiliation":[{"name":"Department of Surgery, Houston Methodist Hospital, Houston, TX."},{"name":"Department of Surgery, Weill Cornell Medical College, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance M.","family":"Mobley","sequence":"additional","affiliation":[{"name":"Department of Surgery, Houston Methodist Hospital, Houston, TX."},{"name":"Sherrie and Alan Conover Center for Liver Disease and Transplantation, Department of Medicine, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukul","family":"Divatia","sequence":"additional","affiliation":[{"name":"Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhna","family":"Dhingra","sequence":"additional","affiliation":[{"name":"Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anaum","family":"Maqsood","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Heyne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY."},{"name":"Division of Medical Oncology, Department of Medicine, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maen","family":"Abdelrahim","sequence":"additional","affiliation":[{"name":"Department of Medicine, Weill Cornell Medical College, New York, NY."},{"name":"Division of Medical Oncology, Department of Medicine, Houston Methodist Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind","family":"Javle","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Nicolas","family":"Vauthey","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Osama","family":"Gaber","sequence":"additional","affiliation":[{"name":"Department of Surgery, Houston Methodist Hospital, Houston, TX."},{"name":"Department of Surgery, Weill Cornell Medical College, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Mark","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"Department of Surgery, Houston Methodist Hospital, Houston, TX."},{"name":"Department of Surgery, Weill Cornell Medical College, New York, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"R1-20250207","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250207","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/SLA.0b013e3182708b57","article-title":"Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections.","volume":"258","author":"Nagino","year":"2013","journal-title":"Ann Surg"},{"key":"R3-20250207","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1093\/annonc\/mdv279","article-title":"Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram.","volume":"26","author":"Groot Koerkamp","year":"2015","journal-title":"Ann Oncol"},{"key":"R4-20250207","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma.","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R5-20250207","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/bjs.10556","article-title":"Surgical resection for Bismuth type IV perihilar cholangiocarcinoma.","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"R6-20250207","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/lv.2000.6143","article-title":"Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma.","volume":"6","author":"De Vreede","year":"2000","journal-title":"Liver Transpl"},{"key":"R7-20250207","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1034\/j.1600-6143.2002.20812.x","article-title":"Radiochemotherapy and transplantation allow long\u2010term survival for nonresectable hilar cholangiocarcinoma.","volume":"2","author":"Sudan","year":"2002","journal-title":"Am J Transplant"},{"key":"R8-20250207","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/SLA.0000000000003801","article-title":"Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma.","volume":"273","author":"Cambridge","year":"2021","journal-title":"Ann Surg"},{"key":"R9-20250207","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1245\/s10434-020-08682-5","article-title":"Center experience affects liver transplant outcomes in patients with hilar cholangiocarcinoma.","volume":"27","author":"Kitajima","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"R10-20250207","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers.","volume":"143","author":"Darwish Murad","year":"2012","journal-title":"Gastroenterology"},{"key":"R11-20250207","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/lt.26285","article-title":"A 3-decade, single-center experience of liver transplantation for cholangiocarcinoma: impact of era, tumor size, location, and neoadjuvant therapy.","volume":"28","author":"Ito","year":"2022","journal-title":"Liver Transpl"},{"key":"R12-20250207","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-2004-828896","article-title":"Liver transplantation for unresectable perihilar cholangiocarcinoma.","volume":"24","author":"Heimbach","year":"2004","journal-title":"Semin Liver Dis"},{"key":"R13-20250207","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/PAS.0000000000000588","article-title":"Prognostic significance of the histologic response of perihilar cholangiocarcinoma to preoperative neoadjuvant chemoradiation in liver explants.","volume":"40","author":"Lehrke","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R14-20250207","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R15-20250207","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"R16-20250207","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus Gemcitabine and Cisplatin in advanced biliary tract cancer.","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"R17-20250207","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.3390\/curroncol29060341","article-title":"Immunotherapy as a neoadjuvant therapy for a patient with hepatocellular carcinoma in the pretransplant setting: a case report.","volume":"29","author":"Abdelrahim","year":"2022","journal-title":"Curr Oncol"},{"key":"R18-20250207","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial.","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"R19-20250207","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2023.5444","article-title":"Abandonment of routine radiotherapy for nonlocally advanced rectal cancer and oncological outcomes.","volume":"10","author":"Hazen","year":"2024","journal-title":"JAMA Oncol"},{"key":"R20-20250207","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative treatment of locally advanced rectal cancer.","volume":"389","author":"Schrag","year":"2023","journal-title":"N Engl J Med"},{"key":"R21-20250207","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"R22-20250207","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study.","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"key":"R23-20250207","first-page":"1","article-title":"Cholangiocarcinoma in sclerosing cholangitis. The role of liver transplantation.","volume":"74","author":"Stieber","year":"1989","journal-title":"Int Surg"},{"key":"R24-20250207","doi-asserted-by":"crossref","first-page":"S215","DOI":"10.1016\/j.annonc.2023.09.1387","article-title":"94MO Advanced extrahepatic cholangiocarcinoma: post-hoc analysis of the ABC-01, -02 and -03 clinical trials.","volume":"34","author":"Lamarca","year":"2023","journal-title":"Ann Oncol"},{"key":"R25-20250207","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R26-20250207","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","article-title":"Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial.","volume":"12","author":"van Gijn","year":"2011","journal-title":"Lancet Oncol"},{"key":"R27-20250207","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0140-6736(09)60484-0","article-title":"Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial.","volume":"373","author":"Sebag-Montefiore","year":"2009","journal-title":"Lancet"},{"key":"R28-20250207","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R29-20250207","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative radiotherapy doses lead to a substantial prolongation of survival in patients with inoperable intrahepatic cholangiocarcinoma: a retrospective dose response analysis.","volume":"34","author":"Tao","year":"2016","journal-title":"J Clin Oncol"},{"key":"R30-20250207","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.adro.2016.10.008","article-title":"Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma.","volume":"1","author":"Sandler","year":"2016","journal-title":"Adv Radiat Oncol"},{"key":"R31-20250207","doi-asserted-by":"crossref","first-page":"zrad025","DOI":"10.1093\/bjsopen\/zrad025","article-title":"Role of neoadjuvant chemoradiotherapy in liver transplantation for unresectable perihilar cholangiocarcinoma: multicentre, retrospective cohort study.","volume":"7","author":"Hoogwater","year":"2023","journal-title":"BJS Open"},{"key":"R32-20250207","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/lt.21107","article-title":"Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma.","volume":"13","author":"Mantel","year":"2007","journal-title":"Liver Transpl"},{"key":"R33-20250207","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000347207","article-title":"Liver transplantation for perihilar cholangiocarcinoma.","volume":"31","author":"Gores","year":"2013","journal-title":"Dig Dis"},{"key":"R34-20250207","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2468-1253(18)30045-1","article-title":"Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.","volume":"3","author":"Lunsford","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R35-20250207","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12014-021-09333-x","article-title":"Combined proteomic\/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan.","volume":"18","author":"Bhat","year":"2021","journal-title":"Clin Proteomics"},{"key":"R36-20250207","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jhep.2015.07.025","article-title":"Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation.","volume":"63","author":"Miltiadous","year":"2015","journal-title":"J Hepatol"},{"key":"R37-20250207","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-022-30708-7","article-title":"The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers.","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"R38-20250207","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.","volume":"73","author":"Montal","year":"2020","journal-title":"J Hepatol"},{"key":"R39-20250207","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41416-022-01932-1","article-title":"Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.","volume":"127","author":"Tomczak","year":"2022","journal-title":"Br J Cancer"},{"key":"R40-20250207","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma.","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"key":"R41-20250207","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management.","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"R42-20250207","article-title":"Randomized prospective multicentric study: radio-chemotherapy and liver transplantation versus liver resection to treat respectable hilar cholangiocarcinoma. ClinicalTrials.gov."}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T20:01:15Z","timestamp":1738958475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001760","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}